(IMVT) Immunovant - Ratings and Ratios
Monoclonal Antibodies, Autoimmune Disease, IMVT-1402, Batoclimab
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 55.4% |
| Value at Risk 5%th | 80.7% |
| Relative Tail Risk | -11.53% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.34 |
| Alpha | -14.34 |
| CAGR/Max DD | 0.25 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.477 |
| Beta | 1.047 |
| Beta Downside | 0.967 |
| Drawdowns 3y | |
|---|---|
| Max DD | 69.88% |
| Mean DD | 33.27% |
| Median DD | 32.77% |
Description: IMVT Immunovant November 09, 2025
Immunovant, Inc. (NASDAQ: IMVT) is a clinical-stage biotech that builds monoclonal antibodies targeting B-cell pathways for autoimmune indications. Its lead pipeline includes IMVT-1402, a CD40-targeted antibody being explored in Graves’ disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy (CIDP), cutaneous lupus erythematosus, and Sjögren’s disease, and batoclimab, which is in development for myasthenia gravis, CIDP, and thyroid eye disease. The firm was spun out of Roivant Sciences in 2018 and is headquartered in New York.
Key quantitative signals (as of the most recent 10-Q filing) show a cash runway of roughly $140 million, enough to fund ongoing Phase 2 trials through late 2025, assuming no major cost overruns. The autoimmune market is expanding at a compound annual growth rate of ~ 7 % (2023-2030), driven by aging demographics and increasing willingness to adopt biologics, which underpins demand for novel agents like IMVT-1402. However, the competitive landscape is dense-major players such as Roche (Roche-approved anti-CD40 antibodies) and AbbVie are advancing similar mechanisms, introducing execution risk that could compress market share if Immunovant’s trials do not meet primary endpoints.
For a data-driven, risk-adjusted assessment of IMVT’s upside potential, the ValueRay platform offers a granular model that can help you evaluate the trade-off between clinical milestones and valuation metrics.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-464.7m TTM) > 0 and > 6% of Revenue (6% = 9600 TTM) |
| FCFTA -0.74 (>2.0%) and ΔFCFTA -21.19pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 318.9k% (prev 29.4k%; Δ 289.6kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.74 (>3.0%) and CFO -431.0m > Net Income -464.7m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 9.07 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (173.6m) change vs 12m ago 18.55% (target <= -2.0% for YES) |
| Gross Margin -78.75% (prev 80.60%; Δ -159.4pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 0.03% (prev 0.29%; Δ -0.26pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -19.75 (EBITDA TTM -486.7m / Interest Expense TTM -24.7m) >= 6 (WARN >= 3) |
Altman Z'' -33.18
| (A) 0.88 = (Total Current Assets 573.5m - Total Current Liabilities 63.3m) / Total Assets 583.0m |
| (B) -2.55 = Retained Earnings (Balance) -1.49b / Total Assets 583.0m |
| warn (B) unusual magnitude: -2.55 — check mapping/units |
| (C) -0.89 = EBIT TTM -487.1m / Avg Total Assets 549.3m |
| (D) -23.48 = Book Value of Equity -1.49b / Total Liabilities 63.3m |
| Total Rating: -33.18 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 26.25
| 1. Piotroski 0.0pt |
| 2. FCF Yield -9.08% |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.00 |
| 5. Debt/Ebitda 1.07 |
| 6. ROIC - WACC (= -99.33)% |
| 7. RoE -84.94% |
| 8. Rev. Trend 12.51% |
| 9. EPS Trend -86.35% |
What is the price of IMVT shares?
Over the past week, the price has changed by +5.92%, over one month by +18.10%, over three months by +76.65% and over the past year by +6.91%.
Is IMVT a buy, sell or hold?
- Strong Buy: 10
- Buy: 3
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the IMVT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 39.3 | 42.6% |
| Analysts Target Price | 39.3 | 42.6% |
| ValueRay Target Price | 29.4 | 6.6% |
IMVT Fundamental Data Overview December 20, 2025
P/B = 10.1493
Beta = 0.558
Revenue TTM = 160.0k USD
EBIT TTM = -487.1m USD
EBITDA TTM = -486.7m USD
Long Term Debt = 98.0k USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 98.0k USD (from shortTermDebt, last fiscal year)
Debt = 98.0k USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -521.9m USD (from netDebt column, last quarter)
Enterprise Value = 4.75b USD (5.27b + Debt 98.0k - CCE 521.9m)
Interest Coverage Ratio = -19.75 (Ebit TTM -487.1m / Interest Expense TTM -24.7m)
FCF Yield = -9.08% (FCF TTM -431.3m / Enterprise Value 4.75b)
FCF Margin = -269.6k% (FCF TTM -431.3m / Revenue TTM 160.0k)
Net Margin = -290.4k% (Net Income TTM -464.7m / Revenue TTM 160.0k)
Gross Margin = -78.75% ((Revenue TTM 160.0k - Cost of Revenue TTM 286.0k) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 8.15 (Enterprise Value 4.75b / Total Assets 583.0m)
Interest Expense / Debt = 4148 % (Interest Expense 4.07m / Debt 98.0k)
Taxrate = -0.47% (negative due to tax credits) (594.0k / -125.9m)
NOPAT = -489.4m (EBIT -487.1m * (1 - -0.47%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 9.07 (Total Current Assets 573.5m / Total Current Liabilities 63.3m)
Debt / Equity = 0.00 (Debt 98.0k / totalStockholderEquity, last quarter 519.7m)
Debt / EBITDA = 1.07 (negative EBITDA) (Net Debt -521.9m / EBITDA -486.7m)
Debt / FCF = 1.21 (negative FCF - burning cash) (Net Debt -521.9m / FCF TTM -431.3m)
Total Stockholder Equity = 547.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -79.71% (Net Income -464.7m / Total Assets 583.0m)
RoE = -84.94% (Net Income TTM -464.7m / Total Stockholder Equity 547.1m)
RoCE = -89.02% (EBIT -487.1m / Capital Employed (Equity 547.1m + L.T.Debt 98.0k))
RoIC = -89.46% (negative operating profit) (NOPAT -489.4m / Invested Capital 547.1m)
WACC = 9.87% (E(5.27b)/V(5.27b) * Re(9.87%) + (debt cost/tax rate unavailable))
Discount Rate = 9.87% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 9.61%
Fair Price DCF = unknown (Cash Flow -431.3m)
EPS Correlation: -86.35 | EPS CAGR: -36.82% | SUE: -0.26 | # QB: 0
Revenue Correlation: 12.51 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS current Year (2026-03-31): EPS=-2.93 | Chg30d=-0.071 | Revisions Net=-1 | Growth EPS=-7.2% | Growth Revenue=+0.0%
EPS next Year (2027-03-31): EPS=-3.00 | Chg30d=+0.049 | Revisions Net=-1 | Growth EPS=-2.3% | Growth Revenue=+0.0%
Additional Sources for IMVT Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle